Trial Profile
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Epirubicin (Primary)
- Indications Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 16 Feb 2022 Planned initiation date changed from 1 Dec 2021 to 1 Mar 2022.
- 16 Feb 2022 Status changed from not yet recruiting to recruiting.
- 16 Feb 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2021 to 1 Mar 2022.